Co-Diagnostics, Inc. (NASDAQ:CODX) Q3 2024 Earnings Call Transcript
Operator: Good afternoon, and welcome to Co-Diagnostics Third Quarter 2024 Earnings Conference Call. [Operator Instructions] Please note, this event is being recorded.
Co-Diagnostics Inc. (CODX)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Renaissance Technologies Jim Simons | 567,722 | $709,653 | -4% | 0% |
| 2. | Citadel Investment Group Ken Griffin | 25,423 | $31,779 | -53% | 0% |
| 3. | 9,100 | $11,375 | +176% | 0% | |
| 4. | 6,700 | $8,375 | +68% | 0% | |
| 5. | Engineers Gate Manager Greg Eisner | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.90 | 3,000 | Officer | 76,236 | 2023-03-20 | Filing | |
| $1.82 | 1,305 | Large Shareholder, Officer, Director | 2,275,000 | 2018-05-11 | Filing | |
| $1.91 | 500 | Large Shareholder, Officer, Director | 2,273,695 | 2018-05-03 | Filing | |
| $2.02 | 500 | Large Shareholder, Officer, Director | 2,273,198 | 2018-04-23 | Filing | |
| $1.94 | 500 | Large Shareholder, Officer, Director | 2,272,698 | 2018-04-16 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $10.46 | 2,000 | 0 | 2021-09-08 | Filing | ||
| $8.53 | 1 | 0 | 2021-05-19 | Filing | ||
| $8.52 | 97,413 | 1 | 2021-05-19 | Filing | ||
| $8.54 | 10,920 | 97,414 | 2021-05-19 | Filing | ||
| $11.00 | 38,046 | Officer, Director | 0 | 2021-01-15 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 1,781,283 | $2,369,107 | 0% | |
| 2. | 501,830 | $667,434 | 0% | |
| 3. | 294,422 | $391,678 | 0% | |
| 4. | 272,900 | $362,957 | 0% | |
| 5. | 145,621 | $193,676 | 0% |
News See All
Co-Diagnostics, Inc. (NASDAQ:CODX) Q2 2024 Earnings Call Transcript
Operator: Good day, and welcome to the Co-Diagnostics Second Quarter 2024 Earnings Conference Call. [Operator Instructions] Please note that this event is being recorded.
Co-Diagnostics, Inc. (NASDAQ:CODX) Q1 2024 Earnings Call Transcript
Co-Diagnostics, Inc. misses on earnings expectations. Reported EPS is $-0.31204 EPS, expectations were $-0.21.
Co-Diagnostics, Inc. (NASDAQ:CODX) Q4 2023 Earnings Call Transcript
Operator: Good day, and welcome to the Co-Diagnostics Fourth Quarter and Full Year 2023 Earnings Conference Call. All participants will be in listen-only mode.
Co-Diagnostics, Inc. (NASDAQ:CODX) Q3 2023 Earnings Call Transcript
Operator: Hello. Welcome to the Co-Diagnostics Third Quarter 2023 Earnings Conference Call. All participants will be in listen-only mode.
Co-Diagnostics, Inc. (NASDAQ:CODX) Q2 2023 Earnings Call Transcript
Operator: Welcome to the Co-Diagnostics Second Quarter 2023 Earnings Conference Call. All participants will be in listen-only mode.
Co-Diagnostics, Inc. (NASDAQ:CODX) Q1 2023 Earnings Call Transcript
Operator: Good afternoon and welcome to the Co-Diagnostics’ First Quarter 2023 Earnings Conference Call. [Operator Instructions] Please note that this event is being recorded today.
Co-Diagnostics, Inc. (NASDAQ:CODX) Q4 2022 Earnings Call Transcript
Operator: Good afternoon, and welcome to the Co-Diagnostics, Inc. Fourth Quarter and Full Year 2022 Earnings Results Conference Call. All participants will be in a listen-only mode.
Co-Diagnostics, Inc. (CODX) Fell Out Of Favor With Hedge Funds
In this article we will analyze whether Co-Diagnostics, Inc. (NASDAQ:CODX) is a good investment right now by following the lead of some of the best investors in the world and piggybacking their ideas.
Where Do Hedge Funds Stand On Co-Diagnostics, Inc. (CODX)?
Hedge funds and large money managers usually invest with a focus on the long-term horizon and, therefore, short-lived dips or bumps on the charts usually don't make them change their opinion towards a...